Alcon refines analyst consensus picture, shares in focus on SIX Swiss Exchange
26.06.2026 - 12:43:58 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-26, 12:43.
Alcon (CH0432492467) starts Friday with a firm analyst backdrop and active trading on the SIX Swiss Exchange. The eye-care specialist remains on many buy lists, with a broad coverage universe providing updated price targets and ratings according to current consensus data.
What analysts currently say
Analyst data compiled by Investing.com shows Alcon covered by a mid-double-digit number of banks and brokers, with the consensus rating described as "Buy" based on recent updates from the healthcare sector. The Investing.com consensus overview highlights that the average 12-month price target for Alcon shares is around the mid-70s in Swiss francs, with individual estimates spanning a broad range.
In that dataset, more than a dozen research houses favor a positive stance on the stock, while only a small minority recommend holding or selling. The distribution underscores that Alcon is still seen as a growth story in the medical-technology and eye-care segment relative to established peers such as Novartis and EssilorLuxottica.
Consensus numbers and valuation frame
According to the same Investing.com consensus, Alcon’s average price target clusters near 77.5 Swiss francs, while the high estimate approaches 90 francs and the low estimate remains just above 50 francs. The consensus page also indicates that the implied upside potential from the current spot level is double-digit in percentage terms, although the spread between the highest and lowest targets signals differing views on execution risk.
Valuation metrics referenced in recent market commentary place Alcon in the mid-range versus the European medical-technology peer group, with a price-earnings ratio above the broader SMI average but closer to specialized healthcare equipment peers. This positioning reflects expectations for steady earnings growth driven by surgical and vision-care demand, while leaving room for both positive and negative revisions if operating trends diverge from models.
All news and analysis on the Alcon shares
Key figures, filings and prior articles on Alcon are available in the dedicated topic area and in the company’s investor-relations section.
The business behind the stock
Alcon generates its revenue in two main segments: surgical products for eye operations and vision care for daily use. The portfolio spans intraocular lenses for cataract surgery, consumables and equipment for ophthalmic procedures, as well as contact lenses and lens-care solutions sold to consumers worldwide.
Where the stock trades today
Alcon shares (CH0432492467) most recently traded on the SIX Swiss Exchange at around 68.13 US dollars per share on the US line on 2026-06-25, 16:00 Eastern Time, according to TradingKey data, while the Zurich listing reflects the corresponding level in Swiss francs. The TradingKey quote overview shows a market capitalization in the mid-30-billion-dollar range for the group.
Key data on the Alcon shares
- Company: Alcon Inc.
- ISIN: CH0432492467
- WKN: A2PDXE
- Ticker: ALC
- Trading venue: SIX Swiss Exchange / NYSE
- Price (as of 2026-06-25, 16:00): 68.13 USD
- Market cap: 34.40 billion USD (as of 2026-06-25)
- Sector / industry: Healthcare equipment and supplies, eye care
- Index membership: Stoxx Europe 600 Health Care
- Next earnings date: not officially scheduled
This article is for informational purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell securities. Investors should conduct their own research and, where appropriate, consult a qualified financial advisor before making investment decisions.
